EP1404681A1 - Procede de preparation de derives de tetrahydrothieno 3,2-c]pyridine - Google Patents

Procede de preparation de derives de tetrahydrothieno 3,2-c]pyridine

Info

Publication number
EP1404681A1
EP1404681A1 EP02745008A EP02745008A EP1404681A1 EP 1404681 A1 EP1404681 A1 EP 1404681A1 EP 02745008 A EP02745008 A EP 02745008A EP 02745008 A EP02745008 A EP 02745008A EP 1404681 A1 EP1404681 A1 EP 1404681A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
thienyl
methyl
chlorophenylglycinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02745008A
Other languages
German (de)
English (en)
Inventor
Stephen E. Horne
Gamini Weeratunga
Bogdan M. Comanita
Jaipal Reddy Nagireddy
Laura Kaye Mcconachie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apotex Pharmachem Inc
Original Assignee
Brantford Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brantford Chemicals Inc filed Critical Brantford Chemicals Inc
Publication of EP1404681A1 publication Critical patent/EP1404681A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention refers to a new process for the synthesis of tetrahydrothieno[3,2-c]pyridine derivatives, in particular 5-o-chlorobenzyl-4,5,6,7- tetrahydothieno[3,2-c]pyridine and racemic or enantiomerically enriched methyl ⁇ -(4,5,6,7-tetrahydro-5-thieno[3,2-c]pyridyl)-o-chlorophenylacetate, and intermediates thereof.
  • Structure 1 known as Ticlopidine, is an antithrombotic drug with platelet aggregation inhibiting properties as disclosed in US 4,051,141 and US 4,127,580.
  • the dextrorotatory enantiomer (Structure 2), bearing the International Non- Proprietary name (INN) Clopidogrel, has the absolute configuration S and is a commercially significant drug with excellent antithrombotic and platelet aggregation inhibiting activity as disclosed in US 4,847,265.
  • the enantiomerically enriched compound can be prepared by means of enantioselective synthesis or starting from a racemic mixture of enantiomers in conjunction with a resolution process.
  • a known process for the preparation of racemic Clopidogrel 2 is based on the nucleophilic displacement of racemic ⁇ -halophenylacetic acid derivatives 3 by 4,5,6,7-tetrahydrothieno[3,2c]pyridine 4 as described in US 4,529,596 and US 5,132,435 (Scheme 1).
  • the enantiomerically enriched clopidogrel is obtained through the resolution of the racemic mixture of methyl ⁇ -(4,5,6,7-tetrahydro-5-thieno[3,2- c]pyridyl)-o-chlorophenylacetate 2 with R-camphorsulfonic acid as described in US 4,847,265 and US 5,132,435.
  • Racemic clopidogrel can also be prepared starting with the Strecker synthesis of ⁇ -(2-thienyl)ethylamino-o-chlorophenylacetonitrile 6 as shown in Scheme 2. Hydrolysis of the nitrile followed by esterification leads to methyl ⁇ -(2- thienyl)ethylamino-o-chlorophenylacetate 8. This in turn generates the tetrahydrothieno[3,2-c]pyridine bicyclic system by reacting with a formylating agent (e.g. paraformaldehyde) under acidic conditions. The process is disclosed in WO 98/51682, WO 98/51689 and WO 98/51681. Scheme 2
  • dextrorotatory clopidogrel can be obtained starting from enantiomerically enriched (R)-sulphonyloxyacetic ester derivatives 11 and 4,5,6,7-tetrahydrothieno[3,2c]pyridine 4 as disclosed in WO 99/18110.
  • the same publication documents the reaction of the methyl (R)- ⁇ -tosyloxy-o- chlorophenylacetate 11 with 2-(2-thienyl)ethylamine 12 to result in methyl (S)- ⁇ - (2-(2-thienyl)ethylamino-o-chlorophenylacetate 8. This in turn generates enantiomerically enriched clopidogrel by reaction with a formylating reagent under acidic conditions. (Scheme 4). Scheme 4
  • the present invention provides an improved process for the preparation of a racemic and enantiomerically enriched 4,5,6,7-tetrahydrothieno[3,2-c]pyridines of general formula I
  • the compound of the general formula I is prepared (Scheme 6) by reducing the compound of formula II with suitable reducing agents, known to those skilled in the art, to a mixture of diastereoisomeric compounds of formula III which are reacted with formaldehyde or any chemical equivalent thereof to yield the compound of formula IV.
  • the compound of formula IV is further rearranged in a suitable solution to produce the compound of formula V which upon reduction (by a suitable reducing agent) provides an enantiomerically enriched or racemic mixture of tetrahydrothieno[3,2-c]pyridine of formula I.
  • X can be hydrogen, carboxyl, alkoxycarbonyl, aryloxycarbonyl, nitrile or carbamoyl of formula
  • Ri and R 2 can be individually or simultaneously hydrogen, alkyl or part of a heterocyclic structure; Y can be hydroxyl, alkanoyloxy, aroyloxy, as well as carbonate derivatives of formula -OCOOR3 or carbamate derivatives of formula -
  • R3 can be substituted or unsubstituted alkyl or aryl
  • R4 and R5 can be individually or simultaneously substituted or unsubstituted alkyl, aryl or cycloalkyl
  • Z can be hydrogen, halogen, alkyl, aryl, aryloxy or alkoxy group.
  • the compound of formula II in its racemic or enantiomerically enriched form is obtained through the reaction of a racemic or enantiomerically enriched primary amine of general formula
  • LG is a leaving group such as halogen, arysulphonyloxy, aryloxy, sulphonate, alkyloxy and its derivatives or activated aryl.
  • Other obvious synthetic chemical equivalents of the phenylglycine counterpart, such as various salts as well as aliphatic or aromatic esters, amides, nitrile or free carboxyl group are also included in the present invention.
  • the reaction may be carried out in an aromatic solvent (e.g. toluene and the like), polar aprotic solvents (e.g.
  • polar protic solvents e.g. methanol, ethanol, propanol, butanol, n-butanol, isobutanol, n-propanol, isopropanol, and the like
  • polar protic solvents e.g. methanol, ethanol, propanol, butanol, n-butanol, isobutanol, n-propanol, isopropanol, and the like
  • the process according to one aspect of the present invention improves the previously reported synthesis of ticlopidine and extends the scope of the synthetic sequence to the structurally related clopidogrel.
  • 2-bromoacetylthiophene 18 and methyl o- chlorophenylglycinate 19 can be prepared according to known literature procedures as reported in Bull. Chem. Soc. Jpn. 60, 1159 and J. Am. Chem. Soc. 1999, 121, 4284 respectively. Racemic or enantiomerically enriched methyl 2-o- chlorophenylglycine 19 reacts with 2-bromoacetylthiophene 18 in the presence of a base which acts as an acid scavenger.
  • novel compounds of formulae 22, 21 and 20 which can be made as a racemic or diasteromeric mixture with set configuration at the carbon adjacent to the nitrogen, as well as its enantiomers either as free base or its salts with Bronstead and Lewis acids.
  • Specific compounds arising from the preparation of formulae 22, 21 and 20 include:
  • Methyl N-2-(2-thienyl)-2-oxoethyl)-o-chlorophenylglycinate (20) (5.4 g, 16.6 mmol) was dissolved in methanol and treated with sodium borohydride (0.69 g, 18.3 mmol). The reaction is allowed to stir at room temperature over the night and treated with 2N hydrochloric acid to acidic pH. Most of the methanol is evaporated under vacuum and then the remaining aqueous solution partitioned between methylene chloride and 5% sodium hydroxide.
  • Methyl N-(2-(2-thienyl)-2-hydoxyethyl)-2-o-chlorophenylglycinate (21) (2.5 g, 7.6 mmol) was dissolved in ethanol and treated with 37% formaline (1.85 g, 22.8 mmol), then heated at 40°C over the night under nitrogen. The ethanol is evaporated under vacuum and the residual water was removed by azeotropic distillation with toluene to provide 2.3 g of desired product as a mixture of diastereoisomers.
  • Methyl N-(2-(2-thienyl)-2-oxoethyl)-2S-o-chlorophenylglvcinate (20) Methyl(S)-o-chlorophenylglycinate (6.5g, 0.032 mol) was dissolved in toluene and treated with potassium carbonate (6.62 g, 0.048 mol) and 2- bromoacetylthiophene (7.2 g 0.035) mol. DMF was added to the reaction mixture and the content was stirred under nitrogen at room temperature. When the whole quantity of aminoester is consumed, the reaction mixture is partitioned between toluene and water and the aqueous layer back extracted several times with toluene. The combined organic phase is extracted with brine, then with 2 N HC1.
  • the aqueous phase was treated with sodium bicarbonate solution to basic pH and extracted with toluene. After the concentration of the toluene solution one obtains
  • Methyl N-(2-(2-thienyl)-2-oxoethyl)-2S-o-chlorophenylglycinate (20) (6.2 g, 19 mmol) was dissolved in methanol and treated in portions with sodium borohydride (0.79 g, 21 mmol) to keep the temperature below 10°C. The reaction is allowed to stir at room temperature for two hours and treated with 2N hydrochloric acid to acidic pH. Most of the methanol is evaporated under vacuum and then the remaining aqueous solution partitioned between methylene chloride and aqueous sodium bicarbonate.
  • Methyl N-(2-(2-thienyl)-2-hydoxyethyl)-2S-o-chlorophenylglycinate (21 ) was dissolved in ethanol and treated with 37% formaline (4.08 g, 50.4 mmol), then heated at 40°C under nitrogen. After four hours, the ethanol is evaporated under vacuum and the residual water was removed by azeotropic distillation with toluene to provide 5.6 g of desired product as a mixture of diastereoisomers.

Abstract

La présente invention concerne un procédé de préparation de dérivés de tétrahydrothiéno[3,2-c]pyridine de formule générale (I), ou leur sels pharmaceutiquement acceptables, dans laquelle: X représente hydrogène, carboxyle, alcoxycarbonyle, aryloxycarbonyle, nitrile, ou carbamoyle de formule (a), dans laquelle: R>1< et R>2< peuvent être séparément ou conjointement hydrogène, alkyle ou une partie d'une structure hétérocyclique; Z peut être hydrogène, halogène, un groupe alkyle, aryle, aryloxy ou alcoxy. Le procédé comprend les étapes suivantes: (a) la réduction du composé de formule (II) avec des agents de réduction appropriés afin d'obtenir un composé de formule (III); (b) la réaction du composé de formule (III) avec du formaldéhyde ou tout équivalent chimique de celui-ci afin d'obtenir un composé de formule (IV); (c) le réarrangement du composé de formule (IV) afin de produire le composé de formule (V), dans laquelle Y est hydroxyle, alcanoyloxy, aroyloxy, des dérivés de carbamate ou de carbonate; et (d) la réduction du composé de formule (V) afin d'obtenir le composé de formule (I).
EP02745008A 2001-07-06 2002-07-05 Procede de preparation de derives de tetrahydrothieno 3,2-c]pyridine Withdrawn EP1404681A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2352520 CA2352520C (fr) 2001-07-06 2001-07-06 Synthese de derives de tetrahydrothieno-[3,2-c]-pyridine
CA2352520 2001-07-06
PCT/CA2002/001017 WO2003004502A1 (fr) 2001-07-06 2002-07-05 Procede de preparation de derives de tetrahydrothieno[3,2-c]pyridine

Publications (1)

Publication Number Publication Date
EP1404681A1 true EP1404681A1 (fr) 2004-04-07

Family

ID=4169420

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02745008A Withdrawn EP1404681A1 (fr) 2001-07-06 2002-07-05 Procede de preparation de derives de tetrahydrothieno 3,2-c]pyridine

Country Status (3)

Country Link
EP (1) EP1404681A1 (fr)
CA (1) CA2352520C (fr)
WO (1) WO2003004502A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100678287B1 (ko) 2005-06-23 2007-02-02 한미약품 주식회사 클로피도그렐의 제조방법 및 이에 사용되는 중간체
US20070191609A1 (en) * 2006-02-13 2007-08-16 Lee Pharma Limited Process for preparation of clopidogrel bisulphate form-1
PL380849A1 (pl) * 2006-10-17 2008-04-28 Adamed Spółka Z Ograniczoną Odpowiedzialnością Krystaliczna postać racemicznego -(2-chlorofenylo)-6,7-dihydrotieno[3,2-c]pirydylo-5(4H)-octanu metylu, sposób jej wytwarzania i zastosowanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2424278A1 (fr) * 1978-04-24 1979-11-23 Parcor Procede de preparation de thieno(2,3-c) et thieno(3,2-c)pyridines
FR2530247B1 (fr) * 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03004502A1 *

Also Published As

Publication number Publication date
CA2352520A1 (fr) 2003-01-06
WO2003004502A1 (fr) 2003-01-16
CA2352520C (fr) 2007-10-02

Similar Documents

Publication Publication Date Title
KR101699095B1 (ko) ２-아실아미노-３-디페닐프로판산의 제조 및 분할 방법
JP4264437B2 (ja) ヒドロキシ酢酸エステル誘導体、その製法及び合成中間体としての用途
EP1772455A2 (fr) Procédé pour la préparation d&#39;un polymorph de l&#39;hydrogensulfate de Clopidogrel
IE73222B1 (en) Process for the preparation of an N-phenylacetic derivatives of tetrahydrothieno [3,2-c] pyridine and its chemical intermediate
ES2209158T3 (es) Resolucion de aminas.
CA2961984C (fr) Nouvelle synthese chirale de n-acyl-(3-substitue)-(8-substitue)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
KR102384529B1 (ko) 4-알콕시-3-(아실 또는 알킬)옥시피콜린아미드의 제조 방법
US6495691B1 (en) Process for the preparation of tetrahydrothieno[3,2-c]pyridine derivatives
JP2011528671A (ja) Ｒ−β−アミノフェニル酪酸誘導体の調製方法
US7763730B2 (en) Method preparation clopidogrel and intermediates used therein
FI91064C (fi) Menetelmä terapeuttisesti vaikuttavien 3-(N-asyylietyyli-aminoalkyyli)-kromaanien ja -1,4-dioksaanien valmistamiseksi
US7057038B2 (en) Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids
CA2352520C (fr) Synthese de derives de tetrahydrothieno-[3,2-c]-pyridine
CN102056914B (zh) 用于制备3,4-二氢-2h-噻吩并[3,2-e]-1,2-噻嗪-4-醇-1,1-二氧化物衍生物和中间体的方法
US20130041150A1 (en) Process for the preparation of chiral beta amino carboxamide derivatives
MXPA04010765A (es) Procedimiento para la preparacion de clopidogrel.
US20150232441A1 (en) Most effective process for base-free preparation of ketone intermediates usable for manufacture of nebivolol
KR100681512B1 (ko) 클로피도그렐의 신규한 제조 중간체 및 이를 이용한 클로피도그렐의 제조방법
ES2300854T3 (es) Procedimiento estereoselectivo para la preparacion de clopidogrel.
CA2058148A1 (fr) Methode de preparation d&#39;un derive de thienopyrane a l&#39;etat d&#39;enantiomere pur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MCCONACHIE, LAURA KAYE

Inventor name: NAGIREDDY, JAIPAL, REDDY

Inventor name: COMANITA, BOGDAN, M.

Inventor name: WEERATUNGA, GAMINI

Inventor name: HORNE, STEPHEN, E.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: APOTEX PHARMACHEM INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041207

RTI1 Title (correction)

Free format text: PROCESS FOR THE PREPARATION OF TETRAHYDROTHIENO ??3,2-C PYRIDINE DERIVATIVES